Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
CUEBOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Cantor Global Healthcare Conference being held in New York, September 3-5, 2025.
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
CUEBOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, announced today the initiation of an investigator sponsored trial (IST) in rGBM at the DFCI with the first patient in the trial having been dosed with CUE-102. The trial (NCT06917885) is a Phase 1b, open-label study of adjuvant CUE-102, the Company’s drug product candidate targeting Wilms’ Tumor 1 protein (WT1) expressing cancers. The principal investigator of the Phase 1b trial, David A. Reardon, MD, is the Clinical Director of the Center for Neuro-Oncology at DFCI and a leader in the field of immunotherapy for the treatment of brain cancer. The goal of the study is to evaluate the tolerability and clinical activity of CUE-102 in patients with GBM at first recurrence.
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
CUEBOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided a business and financial update for the second quarter 2025.
Cue Biopharma CEO Daniel Passeri To Serve As Interim CFO; Kerri-ann Millar Resigns As CFO
CUECue Biopharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $421.00K Miss $1.27M Estimate
CUEReported Earlier, Cue Biopharma Prices $20M Public Offering Of Common Stock And Warrants At $0.79
CUECue Biopharma Announces Proposed Public Offering; No Size Or Amount Disclosed
CUECue Biopharma And Boehringer Ingelheim Announce Strategic Partnership To Develop And Commercialize First-in-Class Bispecific T Cell-Engaging B Cell Depletion Therapy CUE-501 For Autoimmune And Inflammatory Diseases, Aiming For Earlier Intervention And Lon
CUECitizens Capital Markets Reiterates Market Outperform on Cue Biopharma, Maintains $2 Price Target
CUEWhat's Going On With Cue Biopharma Shares Tuesday?
CUECue reported 2024 fiscal-year earnings on Monday after the market closed.
Cue Biopharma FY24 EPS ($0.72) Up From ($1.11) YoY; Revenue $9.287M Up From $5.490M YoY
CUECue Biopharma Q3 2024 GAAP EPS $(0.17) Beats $(0.19) Estimate, Sales $3.336M Beat $1.520M Estimate
CUE